Pricing Log in Create free account

Kairos Pharma, Ltd. (KAPA) vs Virax Biolabs Group Limited (VRAX)

Kairos Pharma, Ltd. and Virax Biolabs Group Limited are both Biotechnology companies. Kairos Pharma, Ltd. and Virax Biolabs Group Limited are of similar size ($1.6M and $1.5M). Across the 10 metrics below, Virax Biolabs Group Limited leads on 6 and Kairos Pharma, Ltd. on 4.

Valuation

Metric KAPA VRAX Biotechnology median
P/E n/m n/m 10.60
P/S n/m — 9.40
P/B 0.36 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.21 0.86 0.66
EV/Sales n/m n/m 9.02
Earnings yield (399.90%) (642.17%) (32.88%)
Free cash flow yield (264.69%) 0.00% (23.13%)

Profitability

Metric KAPA VRAX Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (113.96%) 0.00% (51.96%)
Return on assets (104.32%) 0.00% (46.06%)
Return on invested capital (322.91%) 0.00% 0.00%

Growth

Metric KAPA VRAX Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (30.44%) 68.79% 29.88%
Revenue growth, 5-year CAGR — (36.88%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.98 9.97 4.97
Net debt to EBITDA 1.65 1.08 1.01

Dividend

Metric KAPA VRAX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KAPA VRAX Biotechnology median
Market cap 1.54m 1.58m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack